Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397076 | 0.79 | MAPK14 (0.41) | GCGRKDM4ERAB9AMAPK14MAPK13 | |
| SCHEMBL2339291 | 0.78 | NOTUM (0.48) | KDM4ERAB9ASMN1; SMN2LMNANOTUM | |
| SCHEMBL2785508 | 0.77 | LMNA (0.35) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL27961224 | 0.75 | CYP11B2 (0.44) | GCGRNOTUMCYP19A1MAPK14MAPK13 | |
| SCHEMBL27720322 | 0.75 | KIF11 (0.59) | KDM4ENOTUMMAPK14MAPK13MAPK12 | |
| SCHEMBL18228687 | 0.72 | ATM (0.43) | LMNANOTUMALDH1A1CYP1A2CYP2A6 | |
| SCHEMBL27746508 | 0.72 | PTGS2 (0.43) | SMN1; SMN2MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL27783565 | 0.69 | GAA (0.39) | RAB9ANOTUMNPC1CYP2A6GAA | |
| SCHEMBL28636718 | 0.69 | NOTUM (0.42) | GCGRKDM4ERAB9ASMN1; SMN2NOTUM | |
| SCHEMBL196861 | 0.69 | GCGR (0.67) | GCGRKDM4ERAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287726-A1 | 5-Substituted 1H-Pyrrolo [3,2-B] Pyridines | ALTANA PHARMA AG (DE) | 2007-12-13 | — | — | US | claimed |
| EP-1776361-A1 | 5-SUBSTITUTED 1H-PYRROLOÝ3,2-B¨PYRIDINES | Altana Pharma AG (DE) | 2007-04-25 | — | — | EP | claimed |
| WO-2006013195-A1 | 5-SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINES | ALTANA PHARMA AG (DE) | 2006-02-09 | — | — | WO | claimed |
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-105849097-A | Substituted pyridine derivatives as GSK-3 inhibitors | 百时美施贵宝公司 | 2016-08-10 | — | — | CN | disclosed |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| WO-2008074858-A1 | INTERMEDIATES AND PROCESS FOR THE PRODUCTION OF 5-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| CN-100393720-C | Cyclic benzimidazoles. | ALTANA PHARMA AG (DE) | 2008-06-11 | — | — | CN | disclosed |
| CN-101198594-A | Process for the production of intermadiates for the preparation of tricyclic benzimidazoles | NYCOMED GMBH (DE) | 2008-06-11 | — | — | CN | disclosed |
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113962-A1 | Condensed Tricyclic Benzimidazoles For the Treatment of Gastrointestinal Disorders | AITANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| EP-1414821-A1 | TRICYCLIC EPOXIDES | ALTANA Pharma AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003091253-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003068774-A1 | TRICYCLIC N-ACYL COMPOUNDS | ALTANA PHARMA AG (DE) | 2003-08-21 | — | — | WO | disclosed |
| EP-1332143-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA Pharma AG (DE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003016310-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003014120-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003014123-A1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003014119-A1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002034749-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113962-A1 | Condensed Tricyclic Benzimidazoles For the Treatment of Gastrointestinal Disorders | PGC, SI, VIP | GCGR 127/4885KDM4E 3631/4885RAB9A 2644/4885 |
| US-20070287726-A1 | 5-Substituted 1H-Pyrrolo [3,2-B] Pyridines | GIPR, VIP, PGC | GCGR 67/4885KDM4E 2549/4885RAB9A 986/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | GCGR 18/4885KDM4E 3472/4885RAB9A 2004/4885 |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | GCGR 1808/4885KDM4E 2195/4885RAB9A 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.